Technical Analysis for ARVN - Arvinas, Inc.

Grade Last Price % Change Price Change
grade C 23.06 -3.80% -0.91
ARVN closed down 3.8 percent on Friday, August 23, 2019, on 32 percent of normal volume.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ARVN trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish -3.80%
Inside Day Range Contraction -3.80%
20 DMA Resistance Bearish -3.92%
50 DMA Support Bullish -3.92%
Up 3 Days in a Row Strength -3.92%
Up 4 Days in a Row Strength -3.92%
20 DMA Resistance Bearish -3.88%
Shooting Star Candlestick Bearish -3.88%
50 DMA Support Bullish -3.88%
Doji - Bearish? Reversal -3.88%

Older signals for ARVN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Biopharmaceutical Biology Diseases Genetics Metabolism
Is ARVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 16 David Swensen Sells DocuSign in 2nd quarter
Aug 7 Arvinas To Present at the Wedbush PacGrow Healthcare Conference
Aug 6 JPMorgan upgrades Insulet after strong Q2
Aug 5 Arvinas EPS misses by $0.14, beats on revenue
Aug 5 Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 31 Steven Cohen Charges Into Chiasma
Jul 29 Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
Jul 25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk
Jul 18 Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference
Jul 5 48 Biggest Movers From Wednesday
See more ARVN news...
Indicators
Indicator Value
52 Week High 28.25
52 Week Low 10.19
Average Volume 211,345
200-Day Moving Average 19.813
50-Day Moving Average 24.143
20-Day Moving Average 24.372
10-Day Moving Average 23.851
Average True Range 1.3873
ADX 9.99
+DI 18.8635
-DI 23.0417
Chandelier Exit (Long, 3 ATRs ) 24.0881
Chandelier Exit (Short, 3 ATRs ) 26.6619
Upper Bollinger Band 26.5602
Lower Bollinger Band 22.1838
Percent B (%b) 0.2
BandWidth 17.956672
MACD Line -0.2144
MACD Signal Line -0.0758
MACD Histogram -0.1386
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.89
Resistance 3 (R3) 25.04 24.57 24.59
Resistance 2 (R2) 24.57 24.11 24.50 24.48
Resistance 1 (R1) 23.82 23.82 23.59 23.67 24.38
Pivot Point 23.35 23.35 23.24 23.28 23.35
Support 1 (S1) 22.60 22.89 22.37 22.45 21.74
Support 2 (S2) 22.13 22.60 22.06 21.64
Support 3 (S3) 21.38 22.13 21.54
Support 4 (S4) 21.23